(Hypertension. 1999;33:467-471.)
© 1999 American Heart Association, Inc.
Scientific Contributions |
From the Second Department of Internal Medicine, Faculty of Medicine (M.K., Y.H., H.H., H.N., Y.S., D.N., E.S., M.O.), and Faculty of Pharmaceutical Sciences (K.K., T.N.), University of Tokyo (Japan).
Correspondence to Yasunobu Hirata, MD, The Second Department of Internal Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan. E-mail hirata-2im{at}h.u-tokyo.ac.jp
AbstractThe mechanisms for the
vascular actions of vasodilatory ß-blockers remain undetermined. For
some kinds of ß-blockers, the involvement of nitric oxide (NO) has
been suggested. We studied the effects of vasodilatory ß-blockers on
renal perfusion pressure (RPP) and NO release in the rat kidney.
Infusion of bopindolol, celiprolol, and nebivolol caused a
dose-dependent reduction in RPP and an increase in NO release (RPP:
bopindolol 10-6 mol/L, -23±2%; celiprolol
10-4 mol/L, -27±2%; nebivolol 10-5 mol/L,
-35±3%; NO: bopindolol 10-6 mol/L, +33±2; celiprolol
10-4 mol/L, +41±2; nebivolol 10-5 mol/L,
+45±5 fmol · min-1 · g
kidney-1, mean±SEM). Metergoline (10-6
mol/L), a 5-hydroxytryptamine (5-HT)1/2
antagonist, or NAN-190 (10-6 mol/L), a
5-HT1A antagonist, almost completely abolished
the vasorelaxation and NO release caused by bopindolol, celiprolol, and
nebivolol. However, neither propranolol nor bisoprolol
decreased RPP. Celiprolol and nebivolol caused vasodilation in the rat
thoracic aorta, and it was markedly reduced by
endothelial denudation,
N
-nitro-L-arginine methyl ester
(10-4 mol/L), or NAN-190 (10-6 mol/L). In
deoxycorticosterone acetate-salt hypertensive rats, 4-week
administration of celiprolol (50 mg · kg-1 ·
d-1 IV) restored the responses regarding RPP and NO
release to acetylcholine. These results suggest that several
ß-blockers exert their vasodilatory action through the
5-HT1A receptor/NO pathway and that treatment with these
ß-blockers may protect against endothelial injury
in hypertension.
Key Words: nitric oxide kidney receptors, adrenergic, beta 5-hydroxytryptamine
This article has been cited by other articles:
![]() |
O. Toprak, M. Cirit, M. Tanrisev, C. Yazici, O. Canoz, M. Sipahioglu, A. Uzum, R. Ersoy, and E. Y. Sozmen Preventive effect of nebivolol on contrast-induced nephropathy in rats Nephrol. Dial. Transplant., March 1, 2008; 23(3): 853 - 859. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. McEniery, M. Schmitt, A. Qasem, D. J. Webb, A. P. Avolio, I. B. Wilkinson, and J. R. Cockcroft Nebivolol Increases Arterial Distensibility In Vivo Hypertension, September 1, 2004; 44(3): 305 - 310. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Kobayashi, S.-i. Mita, K. Yoshida, T. Honda, T. Kobayashi, K. Hara, S. Nakano, Y. Tsubokou, and H. Matsuoka Celiprolol Activates eNOS Through the PI3K-Akt Pathway and Inhibits VCAM-1 Via NF-{kappa}B Induced by Oxidative Stress Hypertension, November 1, 2003; 42(5): 1004 - 1013. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Kalinowski, L. W. Dobrucki, M. Szczepanska-Konkel, M. Jankowski, L. Martyniec, S. Angielski, and T. Malinski Third-Generation {beta}-Blockers Stimulate Nitric Oxide Release From Endothelial Cells Through ATP Efflux: A Novel Mechanism for Antihypertensive Action Circulation, June 3, 2003; 107(21): 2747 - 2752. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. W. Broeders, P. A. Doevendans, B. C. A. M. Bekkers, R. Bronsaer, E. van Gorsel, J. W. M. Heemskerk, M. G. A. o. Egbrink, E. van Breda, R. S. Reneman, and R. van der Zee Nebivolol: A Third-Generation {beta}-Blocker That Augments Vascular Nitric Oxide Release : Endothelial {beta}2-Adrenergic Receptor-Mediated Nitric Oxide Production Circulation, August 8, 2000; 102(6): 677 - 684. [Abstract] [Full Text] [PDF] |
||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1999 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |